Our portfolio

Jeito Capital is building a strong and diversified portfolio in Biotech and innovative medical companies.

Neogene Therapeutics

Oncology - Cell Therapy

Acquired by AstraZeneca
November 2022

Round of $110 million
September 2020

Sparing Vision

Ophtalmology - Gene Therapy

Rounds of:
€44,5 million - September 2020
€75 million - Septembre 2022

 

innoSkel

Rare bone Diseases - Gene Therapy

Round of €20 million
December 2020

Pulmocide

Inhaled Respiratory Medicine

Rounds of:
$92 million - May 2021
$52 million - December 2022

Alentis Therapeutics

Fibrotic Diseases Medicine


Round of CHF60 million
June 2021

Quell Therapeutics

T-reg cell therapy in auto-immune and inflammatory diseases


Round of $156 million
November 2021

NMD Pharma

Severe neuromuscular diseases

Round of €35 million
February 2022

EyeBio

Eye disease therapies

Round of $65 million
February 2022

Precirix

Oncology therapies

Round of €80 million
March 2022

CDR-Life

Immuno-oncology therapies

Round of $76 million
April 2022

HI-Bio

Auto-Immune Diseases - Antibody

Round of $120 million
November 2022

CatalYm

Immuno-Oncology Therapies

Round of €50 million
November 2022

At a glance

key data

investments in portfolio

millions euros under management

In short

Discover Jeito news

Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.